摘要:
A pharmaceutical formulation, comprising agomelatine in the form of agamelatine co-crystal with a co-crystal former selected from the group of organic acids in an amount corresponding to 15 - 22 mg agomelatitte dose per one dosage unit and at least one pharmaceutically acceptable excipient for effective treatment of diseases responsive to therapy by agomelatine.
摘要:
The solid solution of aprepitant in a polymer, wherein the polymer is the co-polymer of polyvinyl caprolactam with polyvinyl acetate and polyethylene glycol and the weight ratio of aprepitant to the polymer is between 1:4 and 3:7, a process fro the preparation, and the corresponding pharmaceutical compositions and formulations.